



Universiteit
Leiden
The Netherlands

Dialysis withdrawal and symptoms of anxiety and depression: a prospective cohort study

El-Magd, E.S.; Schouten, R.W.; Nadort, E.; Shaw, P.K.C.; Smets, Y.F.C.; Vleming, L.J.; ... ; Siegert, C.E.H.

Citation

El-Magd, E. S., Schouten, R. W., Nadort, E., Shaw, P. K. C., Smets, Y. F. C., Vleming, L. J., ... Siegert, C. E. H. (2023). Dialysis withdrawal and symptoms of anxiety and depression: a prospective cohort study. *Bmc Nephrology*, 24(1). doi:10.1186/s12882-023-03267-2

Version: Publisher's Version

License: [Creative Commons CC BY 4.0 license](#)

Downloaded from: <https://hdl.handle.net/1887/3753841>

Note: To cite this publication please use the final published version (if applicable).

RESEARCH

Open Access



Dialysis withdrawal and symptoms of anxiety and depression: a prospective cohort study

Essam S. El-Magd^{1*}, Robbert W. Schouten^{1,2}, Els Nadort³, Prataap K. Chandie Shaw⁴, Yves F.C. Smets¹, Louis-Jean Vleming⁵, Friedo W. Dekker⁶, Birit F.P. Broekman^{3,7,8}, Adriaan Honig⁷ and Carl E.H. Siegert¹

Abstract

Background An important aspect of end-of-life decisions in dialysis patients is elective withdrawal from dialysis therapy. Several studies have shown that clinical factors, such as comorbidity, play a role in dialysis withdrawal. The role of symptoms of anxiety and depression is largely unknown. The.

Methods A prospective multi-center study has been set up to investigate anxiety and depressive symptoms longitudinally in dialysis patients. Anxiety and depressive symptoms were investigated using the Beck Anxiety Inventory (BAI) and Beck Depression Inventory (BDI) as baseline. Adverse events, including dialysis withdrawal and mortality were registered during follow-up. Multivariable cox proportional hazard models were used with anxiety and depression as the independent variable and dialysis withdrawal as the outcome variable. Models included age, sex, ethnicity and a set of clinical comorbidities.

Results A total of 687 patients were included between 2012 and 2017, with a median follow-up of 3.2 years. A total of 48 patients (7%) withdrew from dialysis therapy, and subsequently deceased. Anxiety and depressive symptoms at baseline showed an association with dialysis withdrawal with hazard ratios of 2.31 (1.09–4.88) for anxiety and 2.56 (1.27–5.15) for depressive symptoms, independent of somatic comorbidities.

Discussion Withdrawal from dialysis therapy is associated with anxiety and depressive symptoms. Dialysis patients with more severe depressive and anxiety symptoms were more vulnerable for dialysis withdrawal. Insight in factors that play a role in dialysis withdrawal could aid patients and clinicians making an informed decision and develop clinical guidelines.

Keywords Dialysis withdrawal, Anxiety, Depression, Mortality, Dialysis, Kidney disease

*Correspondence:

Essam S. El-Magd
e.s.el-magd@olvg.nl

¹Department of Nephrology, OLVG Hospital, Amsterdam, The Netherlands

²Department of Internal Medicine, Amsterdam UMC, Amsterdam, The Netherlands

³Department of Psychiatry and Medical Psychology, OLVG Hospital, Amsterdam, The Netherlands

⁴Department of Nephrology, HMC Hospital, The Hague, The Netherlands

⁵Department of Nephrology, Haga Teaching Hospital, The Hague, The Netherlands

⁶Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands

⁷Department of Psychiatry, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands

⁸Amsterdam Mental Health, Amsterdam, The Netherlands



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Background

Dialysis withdrawal has become a more common occurrence on the dialysis wards. Recent data shows that withdrawal rates have doubled in the last decade [1–3]. Estimated incidence rate range from 7 to 20% [4, 5]. The variation is partly explained due to a high degree of heterogeneity in the definition of withdrawal from dialysis [6–8]. A recent study identified age, sex, recently starting dialysis and somatic comorbidities as potential risk factors for dialysis withdrawal. The authors do note that psychiatric comorbidities, such as depression, could be associated with dialysis withdrawal, but that no psychiatric data was collected [10].

Anxiety and depression are the most common psychiatric comorbidities among dialysis patients with an estimated prevalence of 15–38% for anxiety and 37–42% for depressive symptoms. Data on the role of psychiatric factors influencing dialysis withdrawal is scarce [9, 10]. Only one smaller study in 2006 with 202, mostly Caucasian (90%), dialysis patients has investigated the association between depression and dialysis withdrawal, which showed an increased risk of withdrawal when patients reported depressive symptoms [5]. Another study by Lacson et al., which used the mental component scores of the SF-36 as a marker for depression found a similar association [11]. To the best of our knowledge there has been no data on the association between anxiety symptoms and withdrawal.

Currently it is unknown how to handle symptoms of depression and anxiety in relation to end-of-life care options in end-stage renal disease patients [4, 12]. Identification of factors influencing dialysis continuation or withdrawal could aid in making informed decisions to withdraw from dialysis therapy.

The primary aims of this study are to investigate the association between: (1) depressive symptoms and dialysis withdrawal, and (2) anxiety symptoms and dialysis withdrawal. Secondary aims are to investigate the relationship between mental and physical component scores of Quality of Life (QoL) questionnaires and dialysis withdrawal.

Methods

Study cohort and follow-up

Data was collected from the observational prospective cohort study Depression-related factors and outcomes In dialysis patients with Various Ethnicities and Races Study.

(DIVERS) [10, 13–17]. The study cohort consisted of prevalent and incident dialysis patients from 10 dialysis centers in the Netherlands. These include 2 centers of the OLVG hospital, 2 centers of the HMC hospital, 3 centers of the Haga hospital and 3 centers of the VUmc university hospital. Patients were included between June 2012

and October 2016. All patients who met the inclusion criteria were approached for study participation during dialysis treatment or during an outpatient appointment for patients receiving peritoneal dialysis therapy. Inclusion criteria were being at least 18 years of age and having a dialysis vintage of at least 90 days. Patients who were unable to fill in self-reported questionnaires were excluded. To improve generalizability, all questionnaires and variables were available in Dutch, English, Turkish, and Moroccan Arabic translations, furthermore patients with disabilities or illiteracy which impaired them to fill in the questionnaires, were helped by a trained research assistant. Before inclusion, all patients gave informed consent. Legal guardians signed informed consent for participants who were unable to sign the informed consent themselves, either due to cognitive disabilities or illiteracy. Patients who receive renal replacement therapy in the Netherlands are fully covered by an obligatory healthcare insurance. Patients on dialysis therapy are fully covered by all public healthcare insurance policies [18]. This study was approved by the medical ethics committees of all participating hospitals and was carried out in accordance with the Declaration of Helsinki.

Demographic and clinical data

At baseline, the following sociodemographic and clinical data were collected from electronic medical records: age, sex, dialysis modality and vintage, comorbid conditions, transplant waiting list status and current medication use. Incident patients were defined as new patients on renal replacement therapy for more than 90 days and less than 180 days. The primary cause of kidney disease was classified according to the European Renal Association–European Dialysis and Transplant Association (ERA-EDTA) coding system and divided into 4 groups (diabetes mellitus, glomerulonephritis, renal vascular disease, and other) [19]. The level of comorbidity was defined according to the Davies comorbidity index, indicating no, intermediate or severe comorbidity, this 3-point severity index was used in the multivariable analyses [20]. We collected the following characteristics through self-reported questionnaires: immigrant status (defined as immigrant status based on the country of birth) [21], marital status, number of children, educational level, religion, employment status, current smoking and alcohol use, and previous depression.

Depressive and anxiety symptoms and quality of life

Baseline depressive and anxiety symptoms were measured using self-report questionnaires, The Beck Depression Inventory second edition (BDI-II) and Beck Anxiety Inventory (BAI), respectively [22, 23]. Both questionnaires consist out of 21 questions relating to cognitive and somatic symptoms of depression and anxiety.

Respondents were asked to rate the severity of each of these symptoms in the past week on a scale ranging from 0 to 3; not at all to severely burdened. A total score was calculated by summing all items, with a minimum of 0 and maximum of 63.

Both the BDI and BAI have been validated in a large variety of cohorts of patients with various anxiety and depressive disorders diagnosed with the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, 4th. Edition (SCID-1), including cohorts of patients with other chronic somatic diseases. This study used validated BAI translations in Dutch, English, Turkish and Moroccan Arabic. The BDI-II and BAI both have high internal consistency, respectively a Cronbach α of 0.91 and a Cronbach α of 0.92. The BDI-II has a high one-week test-retest reliability of 0.93 and the BAI has a reliability of 0.75 [22, 24–26].

The presence of depressive and anxiety symptoms was also dichotomized by using cut-off values. For the BDI, a cut-off value of ≥ 13 was used as this cut-off value has been validated in a Dutch cohort of dialysis patients [27]. For the BAI, the cut-off of ≥ 16 was used in the analyses was based on the manual provided by Beck and Steer indicating “clinically significant” anxiety symptoms. Despite the frequent use of the BAI in patient groups with somatic diseases, this cut-off value for the BAI has not yet been validated in dialysis patients. In this study the term ‘anxiety’ and ‘depression’ refers to patients who scored above the predefined cut-off scores for clinically relevant symptoms, not to a clinical diagnosis based on the DSM-5. Furthermore, patients who answered the question on the BDI related to suicidal ideation were screened afterwards for active suicidal thoughts or plans. Patients who were deemed to have a heightened risk for suicide were excluded from the study and their primary physician were informed to facilitate further treatment or aid.

Quality of Life (QoL) was measured using the 12-Item Short Form Health Survey (SF-12), which includes a Mental component score (MCS) and a Physical component score (PCS) [28]. The medical outcome survey Short Form 12 (SF-12) has been widely used and validated as a quality of life (QoL) assessment tool in dialysis patients [29]. Furthermore, studies have shown that the SF-12 is associated with all-cause mortality in chronic dialysis patients [29]. To the best of our knowledge, no cut-off score for dialysis patients has been validated. To dichotomize the result the median value of the MCS and PCS will be used as cut-off value to compare patients below and above the median value. Both the continuous score of the MCS and PCS subscales of SF-12 and the dichotomized variables of the SF-12 MCS and PCS subscales will be used in the analyses.

Assessment of outcome: dialysis withdrawal

Mortality and withdrawal rates were extracted from medical records. Cause of death was first classified according to the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) coding system [19]. All mortalities were then evaluated by examination of medical records and physician notes. Dialysis withdrawal was defined as a patient preference to acutely stop with dialysis therapy without an immediate medical reason or indication to stop the dialysis therapy. This medical indication was judged and coded by the treating physician. If the records were not clear, the primary physician was interviewed.

Statistical analysis

All statistical analyses were performed using either SPSS for Windows, version 24 (IBM Corp), and R-studio version 3.5.3. Baseline characteristics were stratified by the presence or absence of symptoms of depression or anxiety, defined as patients scoring above or below the predefined cutoff scores of ≥ 13 and ≥ 16 respectively. Incidence rates of dialysis withdrawal will be calculated using events per 1000-person year using follow-up time in days after inclusion in the DIVERS study and number of events.

Cox proportional hazard regression analysis was used to calculate crude Hazard Ratio's (HR) to determine the relative risk of anxiety and/or depression on dialysis withdrawal. Multivariate adjustment of the crude HR's was performed to adjust for possible confounders using the following variables; age, sex, ethnicity and comorbidity using the Davies comorbidity score in 3 severity categories. An a priori sequential order in the regression model was used to examine the effect of these possible confounders in the following steps:

1. Crude, univariable exposure (depression or anxiety or both).
2. Adding age, sex and ethnicity to the model.
3. Adding comorbidity to model 2.

Primary analyses will focus on model 2 and model 3. All regression models will be tested separately for anxiety symptoms and depressive symptoms and for the combination of both anxiety and depression.

Secondary analyses include analyzing the continuous BDI and BAI scores, the continuous MCS and PCS scores of the SF-12 QoL and the dichotomized MCS and PCS variable of the SF-12 QoL and their association with dialysis withdrawal using the same multivariate model described above. Furthermore, to assess the impact of missing data on results BDI and BAI scores were imputed using multiple imputation (10 repetitions.)

Lastly, patients' characteristics will be summarized using a stratification on the outcome: dialysis withdrawal. This table will be used to provide insight in patients'

characteristics that might be associated with dialysis withdrawal. This step will be viewed as explorative without formal tests, which could aid in raising new research questions.

Sensitivity analyses

A sensitivity analysis excluding patients who received a kidney transplant during follow-up will also be performed. Dialysis populations are extremely heterogeneous, with certain patients having no hope of ever receiving a transplant due to health reasons or otherwise compared to others who still have an option for transplant. Patients with no other option than dialysis are faced with the fact that they have to spend the rest of their lives on dialysis. Faced with these reality patients are likely more prone to develop reactive depression to their situation. This sensitivity analysis will attempt to correct for this by excluding patients who received a kidney transplant.

Results

Baseline characteristics

Baseline characteristics of the total cohort of 687 patients are shown in Table 1. The mean age was 65 ± 15 years, and 62% of the patients were male. The cohort was multi-ethnic and multi-religious, with 300 (48%) participants having an immigration background, 99 (17%) participants being a Muslim, 213 (36%) Christian and 44 (7%) Hindu. Most patients were on hemodialysis (88%), with 203 (30%) of the patients being on the waiting list for kidney transplantation. Both incident (37%) and prevalent (63%) patients were included, with an average dialysis vintage for prevalent patients of 13 months [IQR: 4–47]. The maximum follow-up was 4 years, with a median follow-up of 3.1 years. Patients with depressive symptoms above the cut-off value had an average BDI score of 21.6 ± 8.1 and an average BAI score of 16.3 ± 10.9 and those without clinically significant symptoms had averages BDI scores of 6.4 ± 3.4 and BAI scores of 5.6 ± 6.0 . Patients with anxiety symptoms above the cut-off value also had higher average BAI scores of 25.4 ± 9.5 and BDI scores of 22.7 ± 10.4 compared to those with anxiety symptoms below the cut-off, who had average scores of 6.0 ± 4.5 and 9.9 ± 7.4 for BAI and BDI respectively. Suicidal thoughts were present in 36 patients (11%), measured using item 9 on the BDI.

Incidence of withdrawal

A total of 48 patients (7%) withdrew from dialysis therapy during the follow-up of this study, and subsequently passed away. Supplementary table S1 shows the incidence rates of dialysis withdrawal per 1000 person years (py), stratified by the presence of anxiety and depression. Patients who scored above the cut-off value for depressive symptoms showed a withdrawal rate of 40.4/1000

py compared to 27.0/1000 py for patients below the cut-off value, which results in an absolute risk increase of 13.4 withdrawals / 1000 py. For anxiety symptoms, the increase was 6.3 withdrawals / 1000 py. These crude results, without adjusting for confounding, indicated that there is an increase in incidence rate of withdrawal with symptoms of anxiety and/or depression above the clinical cut-off.

Association between anxiety, depression and dialysis withdrawal

Kaplan Meier plots showed an increased risk of dialysis withdrawal in patients who scored above the cut-off value for depression and anxiety, as shown in Fig. 1. The primary analyses using cox proportional hazard regression models are shown in Table 2. The primary analyses included two models; model 1, which includes age, gender and ethnicity and model 2, which additionally includes the Davies comorbidity score besides the variables from model 1. Patients with depressive symptoms had a 2-fold increase in risk of dialysis withdrawal during follow-up, with a Hazard Ratio (HR) of 2.56 (CI: 1.27–5.15, $p=0.009$, model 1 in Table 2). When comorbidities were included in the model, the HR did not show a major change with a HR of 2.44 (CI: 1.21–4.93, $p=0.0013$, Model 2 in Table 2). When accounting with multiple imputation patients with depressive symptoms still had around a 2-fold increase in risk of dialysis withdrawal when fully corrected, with a HR of 1.95 (1.04–3.77, $p=0.046$, Model 2 in supplementary Table S4a).

For anxiety symptoms a similar trend was seen, with an increased risk for dialysis withdrawal for patients who scores above the cut-off value, (HR 2.31 (CI: 1.09–4.88, $p=0.028$, model 1 in Table 2)). After the inclusion of comorbidities, the HR and corresponding 95% confidence interval slightly decreased, with a HR of 2.02 (CI: 0.94–4.32, $p=0.071$, Model 2 in Table 2). When accounting for missing with multiple imputation the HR decreased to 1.65 (CI: 0.73–3.73, $p=0.226$, Model 2 in supplementary Table S4a). Patients with both anxiety and depressive symptoms above the cut-off ($BDI \geq 13$ and $BAI \geq 16$) had a slight increase in HR compared to the HR from depression and anxiety alone, with a HR of 2.45 in the fully adjusted model (CI: 1.05–5.71, $p=0.037$, model 2 in Table 3). Similar to when looking at depression and anxiety alone, accounting for missing with multiple imputation decreased the HR to 1.99 (CI: 1.25–3.17, $p=0.004$, Model 2 in supplementary Table S4a). When this group is compared with patients with less symptoms of depression or anxiety, the HR was 3.82 (CI: 1.48–9.86, $p=0.006$, data not in table). Overall, these results suggest a 2-fold increase in risk for dialysis withdrawal in patients with anxiety and/or depressive symptoms.

Table 1 Baseline characteristics of the Divers cohort

	Anxiety ^a			Depression ^b	
	All <i>n</i> = 687	No <i>n</i> = 395	Yes <i>n</i> = 113	No <i>n</i> = 305	Yes <i>n</i> = 228
Demographic					
Age (years)	64 ± 15	65 ± 15	62 ± 14	65 ± 16	64 ± 14
Male	424 (62%)	249 (63%)	71 (63%)	208 (68%)	143 (63%)
Ethnicity (% immigrant)	300 (47.8%)	163 (43%)	67 (61%)	124 (40.7%)	123 (56%)
. European	366 (58%)	244 (64%)	45 (41%)	193 (65%)	109 (49%)
. Sub-Saharan	22 (4%)	13 (3%)	2 (2%)	15 (5%)	5 (2%)
. North-Africa/Western Asia	54 (9%)	19 (5%)	17 (16%)	17 (6%)	21 (10%)
. South/South-East. Asia	57 (9%)	33 (9%)	14 (13%)	24 (8%)	24 (11%)
. South America/Caribbean	131 (21%)	75 (20%)	32 (29%)	50 (17%)	62 (28%)
Social					
Married	316 (52%)	207 (52%)	55 (49%)	172 (57%)	114 (50%)
Has children	474 (78%)	306 (78%)	87 (78%)	233 (77%)	179 (79%)
Low formal education	332 (56.7%)	201 (51%)	70 (64%)	151 (51%)	133 (60%)
Religion	220 (37%)	159 (41%)	32 (29%)	123 (41%)	76 (34%)
. None	213 (36%)	144 (37%)	32 (29%)	115 (38%)	75 (33%)
. Christian	99 (17%)	48 (12%)	33 (30%)	38 (13%)	46 (20%)
. Islamic	44 (7%)	24 (6%)	12 (11%)	18 (6%)	21 (9%)
. Hinduism	21 (4%)	13 (3%)	3 (3%)	7 (2%)	8 (4%)
. Other					
Not employed	534 (89%)	336 (86%)	107 (95%)	258 (85%)	207 (91%)
Renal and Dialysis					
Incident Patient	240 (36%)	154 (39%)	34 (30%)	122 (40%)	77 (34%)
Dialysis vintage (months)	13 [4–47]	11 [4–45]	28 [5–57]	8 [4–39]	15 [4–48]
Treatment modality:	601 (88%)	344 (87%)	101 (89%)	274 (89%)	198 (87%)
. Hemodialysis	84 (12%)	51 (13%)	12 (11%)	34 (11%)	30 (13%)
. Peritoneal dialysis					
Primary kidney disease:	155 (24%)	82 (23%)	38 (36%)	56 (20%)	65 (30%)
. Diabetic Nephropathy	163 (26%)	100 (28%)	18 (17%)	71 (26%)	50 (23%)
. Renal vascular disease	70 (11%)	40 (10%)	11 (10%)	35 (13%)	22 (10%)
. Glomerulonephritis	247 (39%)	140 (39%)	40 (37%)	115 (42%)	79 (37%)
. Other					
On waiting list for Tx:	203 (30%)	126 (32%)	30 (27%)	104 (34%)	69 (30%)
. Yes	436 (64%)	245 (62%)	72 (64%)	179 (59%)	148 (65%)
. No, for medical reasons	46 (7%)	24 (6%)	11 (10%)	22 (7%)	11 (5%)
. No, by patient preference					
Clinical					
Current smoking	108 (18%)	68 (18%)	23 (21%)	53 (18%)	48 (21%)
Current alcohol use	161 (27%)	110 (28%)	27 (24%)	94 (31%)	53 (24%)
Davies comorbidity score:	183 (27%)	109 (29%)	24 (21%)	90 (31%)	51 (23%)
. None	370 (55%)	212 (55%)	58 (52%)	156 (53%)	133 (59%)
. Intermediate	119 (18%)	62 (16%)	30 (27%)	49 (17%)	43 (19%)
. Severe					
Diabetes mellitus	288 (42%)	158 (40%)	58 (52%)	117 (38%)	123 (54%)
Ischemic heart disease	190 (28%)	97 (25%)	41 (36.4%)	77 (26%)	71 (31%)
Peripheral vascular disease	168 (25%)	99 (26%)	27 (24%)	65 (22%)	60 (26%)
Mental health:					
Previous depression	27 (4%)	12 (3%)	6 (5%)	9 (3%)	12 (5%)
Antidepressant use	65 (10%)	28 (7%)	15 (13%)	22 (7%)	28 (12%)
Depression:	12.9 ± 9.6	9.9 ± 7.4	22.7 ± 10.4	6.4 ± 3.4	21.6 ± 8.1
. BDI Score	228 (33%)	110 (30%)	80 (83%)	-	-
. BDI ≥ 13	64 (11%)	30 (8%)	23 (21%)	6 (2%)	51 (22%)
. Suicidal thoughts (item 9)*					

Table 1 (continued)


	All <i>n</i> = 687	Anxiety ^a		Depression ^b	
		No <i>n</i> = 395	Yes <i>n</i> = 113	No <i>n</i> = 305	Yes <i>n</i> = 228
Anxiety:	10.3 ± 10.1	6.0 ± 4.5	25.4 ± 9.5	5.6 ± 6.0	16.3 ± 10.9
. BAI Score	113 (22%)	-	-	16 (6%)	80 (42%)
. BAI ≥ 16					
Quality of Life:	38.1 ± 11.1	38.2 ± 10.5	33.0 ± 10.1	40.3 ± 10.4	32.9 ± 9.4
. Physical component score	48.9 ± 10.8	50.9 ± 9.5	40.0 ± 11.3	52.0 ± 8.5	41.8 ± 11.0
. Mental component score					

Values are presented as mean ± SD, median [IQR] or frequency (percentage).

^a The presence of depression is defined as a BDI score ≥ 13

^b The presence of anxiety is defined as a BAI score ≥ 16

^c Using a grouping variable based on item 9 of the BDI: When patients scored a 1 or higher, they were dichotomized into the group with suicidal thoughts.

**Fig. 1** Kaplan Meier curves on cumulative dialysis withdrawal stratified by the presence of anxiety and depressive symptoms

^aThe cut-off value for depressive symptoms was BDI ≥ 13.

^bThe cut-off value for anxiety symptoms was BAI ≥ 16.

Table 2 Association between depression, anxiety and dialysis withdrawal

<i>Hazard ratio's for dialysis withdrawal</i>	Crude	Model 1 (+ age, gender, ethnicity)	Model 2 (+ comor- bidity)
Depressive symptoms ^a	1.64 (0.83–3.25) <i>p</i> = 0.156	2.56 (1.27–5.15) <i>p</i> = 0.009	2.44 (1.21–4.93) <i>p</i> = 0.013
Anxiety symptoms ^b	1.35 (0.66–2.79) <i>p</i> = 0.411	2.31 (1.09–4.88) <i>p</i> = 0.028	2.02 (0.94–4.32) <i>p</i> = 0.071
Both depression and anxiety symptoms ^c	1.95 (0.87–4.38) <i>p</i> = 0.106	3.10 (1.35–7.11) <i>p</i> = 0.008	2.45 (1.05–5.71) <i>p</i> = 0.037

Model 1 includes both the exposure + age, gender and ethnicity

Model 2 includes both the variables from model 1 + additionally the DAVIES comorbidity score, which includes points for ischemic heart disease, heart failure, peripheral vascular disease, malignancy, diabetes, collagen vascular disease, COPD and others

^a The presence of depression is defined as a BDI score ≥ 13

^b The presence of anxiety is defined as a BAI score ≥ 16

^c Based on a grouping variable with both the BDI ≥ 13 AND BAI ≥ 16 versus patients with only anxiety or only depression or none

Table 3 Association between quality of life and dialysis withdrawal

<i>Hazard ratios for dialysis withdrawal</i>	Crude	Model 1 (+ age, gender, ethnicity)	Model 2 (+ comor- bidity)
Mental component score SF-12 < 50.0*	1.41 (0.78–2.53) p=0.254	1.91 (1.05–3.49) p=0.034	1.81 (0.99–3.30) p=0.053
Physical component score SF-12 < 37.0*	1.61 (0.89–2.91) p=0.116	1.51 (0.83–2.74) p=0.178	1.26 (0.69–2.30) p=0.463

Model 1 includes both the exposure + age, gender and ethnicity

Model 2 includes both the variables from model 1 + additionally the DAVIES comorbidity score, which includes points for ischemic heart disease, heart failure, peripheral vascular disease, malignancy, diabetes, collagen vascular disease, COPD and others

* The higher the score on the SF-12, the better the Quality of Life. A cut-off of 50 was used for the MCS and 37 for the PCS.

Table 4 Baseline characteristics stratified by dialysis withdrawal, death to other cause and no withdrawal

<i>Baseline characteristics</i>	With- drawal n=48	Death by other cause* n=122	No withdrawal** n=621
Age (years)	77 ± 11	71 ± 11	63 ± 15
Male	30 (63%)	77 (63%)	382 (61%)
Ethnicity (% immigrant)	10 (22%)	45 (40%)	281 (50%)
. European	40 (87%)	75 (67%)	320 (56%)
. Sub-Saharan	0 (0%)	0 (0%)	22 (4%)
. Northern Africa/Western Asia	0 (0%)	5 (5%)	51 (9%)
. Southern Asia/South Eastern Asia	4 (9%)	10 (9%)	51 (9%)
. South America/Caribbean	2 (4%)	22 (20%)	126 (22%)
Married	22 (52%)	55 (53%)	290 (53%)
Has children	35 (83%)	92 (88%)	432 (79%)
Low education	211 (38%)	45 (48%)	23 (55%)
Employed	0 (0%)	8 (8%)	64 (12%)
Dialysis vintage (months)	33 [6–53]	21 [5–52]	12 [4–45]
Peritoneal Dialysis	6 (13%)	10 (8%)	74 (12%)
Central venous catheter	8 (17%)	13 (11%)	81 (13%)
Residual diuresis > 100 ml/24 h	33 (69%)	79 (65%)	439 (71%)
On waiting list for Tx	1 (2%)	13 (11%)	200 (32%)
DAVIES comorbidity scale:	6 (13%)	19 (16%)	176 (28%)
. No	24 (50%)	67 (55%)	345 (56%)
. Intermediate	18 (38%)	36 (30%)	100 (16%)
. Severe			
Comorbidities:	25 (52%)	67 (55%)	259 (42%)
. Diabetes mellitus	14 (29%)	27 (22%)	96 (16%)
. Heart failure	15 (31%)	27 (18%)	69 (11%)
. Peripheral vascular disease			
Mental health:	18 (55%)	38 (43%)	207 (43%)
. Depression (BDI ≥ 13)	14 ± 7	14 ± 11	13 ± 10
. BDI score	10 (26%)	23 (30%)	100 (22%)
. Anxiety (BAI ≥ 16)	12 ± 8	13 ± 12	10 ± 10
. BAI score	49 ± 10	48 ± 12	49 ± 11
. Mental score SF-12	35 ± 11	36 ± 12	38 ± 11
. Physical score SF-12			

* The 'Death by other cause' group is mutually exclusive with the 'Withdrawal' group

** The 'No withdrawal' group is the total cohort minus the withdrawal group, this includes patients who died by other causes, who underwent a transplantation or were otherwise censored in the cox models

Association between quality of life and dialysis withdrawal

The associations between the QoL component scores and dialysis withdrawal are shown in Table 3 and Supplementary Table 5b. The mental component score showed a HR of 1.91 for dialysis withdrawal (CI:1.05–3.49, p=0.034, Model 1 in Table 3), where the physical component score showed a non-significant HR of 1.51 (CI: 0.83–2.74, p=0.178, Model 1 in Table 3). To investigate the effect of the physical quality of life score on the association between depression/anxiety and withdrawal we did an additional analysis using Model 3, in which we added the physical component score as a covariate. Results from this analysis indicated no major differences in the associations between depression/anxiety and withdrawal with a HR of 2.2 (1.04–4.67, p=0.040) for depression and a HR of 1.95 (0.91–4.17, p=0.087) for anxiety. These results indicate that the association between anxiety, depression and dialysis withdrawal is largely independent from the physical component of the QoL score.

Characteristics of patients who withdrew from dialysis therapy

Characteristics of patients who withdrew from dialysis therapy are described in Table 4. Compared to the total cohort, patients who withdrew from dialysis therapy had a longer dialysis vintage, older age, higher education level and slightly more comorbidities. Of the patients who withdrew, 98% were not on the waiting list for transplantation, 55% scored high on the depression scale and 26% on the anxiety scale. The QoL scores did not show major differences compared to other patients.

Almost all patients who withdrew from dialysis therapy were native patients from European origin. Interestingly, none of the 99 Muslim patients withdrew from dialysis, as shown in Supplementary table S2, while 5–7% of the Christian or Hindu patients withdrew from dialysis therapy.

Sensitivity analyses

Sensitivity analysis performed on the complete case dataset without patients who received transplant shows similar data to our primary analysis, as shown in Supplementary table S4b. A total of $n=28$ patients received a transplant during follow-up and were excluded from the sensitivity analysis.

Furthermore, the observational data in Table 4 suggest that education level and dialysis vintage are more strongly associated with dialysis withdrawal than sex. Since our statistical analysis plan was established a priori, we did not change our main analyses, instead we performed 2 additional sensitivity analyses which included education level or dialysis vintage as a covariate instead of sex. These models did not show major differences compared to the original intended models, as shown in Supplementary table S3a and S3b. Furthermore,

Discussion

The aim of this study was to investigate if anxiety and depressive symptoms increased the risk of dialysis withdrawal in End-Stage Kidney Disease (ESKD) patients. During the follow-up of the included 687 dialysis patients, 48 patients decided to electively withdraw from dialysis therapy. High anxiety and depressive symptoms were associated with dialysis withdrawal with hazard ratios of 2.31 (1.09–4.88) for anxiety, 2.56 (1.27–5.15) for depression and 2.45 (1.05–5.71) for concurrent anxiety and depressive symptoms in a multivariable model including age, gender and ethnicity. When somatic comorbidity was included in these models the hazard ratios showed only minor changes, indicating that the effect of anxiety and depressive symptoms on dialysis withdrawal is independent of somatic comorbidities. Likewise, especially the MCS of the SF-12 compared to the PCS of the SF-12 QoL questionnaire increased the risk on dialysis withdrawal with an HR of 1.91 (CI: 1.05–3.49) and HR 1.51 (CI: 0.83–2.74), respectively. Furthermore, these symptoms of depression and anxiety were found to be stable over time and did not show a large variation, as described in another paper with a mixed-model analyses which showed no significant changes in the BDI and BAI scores between the 6-month-interval time points in the same cohort as described in this paper [30].

Current literature shows varying incidence rates of dialysis withdrawal, possibly due to heterogeneous study design and definitions of withdrawal [6–8]. There are no studies on the effect of anxiety on dialysis withdrawal. Only one study investigated the association between depressive symptoms and dialysis withdrawal using a validated questionnaire. While similar to this study being a prospective observational study with self-report questionnaires the study had a comparatively small sample size with 202 patients. This study by McDade et al. found

a 1-point increase in the total BDI score was associated with a 5.2% increase in risk of withdrawing [5]. This is in concordance with our cohort of 687 patients which shows a 3.3% increase in risk per point increase on the BDI (supplementary table S5a). Besides the study by McDade one other prospective observational study by Lacson et al. with 6415 patients found similar results when using the 5-item mental health score from the SF-36 questionnaire, where a 1-point increase in depression score was associated with a HR for withdrawal of 1.19 (CI: 1.08–1.31) [11]. However this questionnaire has not been validated for use in the dialysis population for symptoms of depression.

There are also some differences between these previous studies and our present study. First of all, in contradiction to the other studies, we were able to explore the effect of somatic comorbidity on the associations between depressive symptoms and dialysis withdrawal. This is important as anxiety and depression are associated with somatic complaints [10, 31, 32]. Our results indicated however, that somatic comorbidity showed no major changes to the associations between both depression and withdrawal, and anxiety and withdrawal. Second, while McDade had a homogeneous ethnic sample (90% Caucasian). This study replicates these results in a multi-ethnic urban cohort with 49% immigrant patients. Lacson did have a more heterogeneous population with 30% non-white patients, however as mentioned above they did not use a depression specific questionnaire that was previously validated in the dialysis population.

Interestingly, our study in a multi-ethnic sample suggests that ethnicity and religion are also associated with dialysis withdrawal. This is not surprising as it is known that certain cultural and religious beliefs are protected factors for end-of-life decisions [33–36]. Future studies are needed to investigate these differences in larger samples.

Strengths and limitations

This study needs to be interpreted with the following limitations in mind. First, the prospective design of this study is one of the major strengths, however it does limit us in the number of events. Although dialysis withdrawal is one of the main causes of death in this sample, the total number of events is 48, which limited our ability to include a large set of possible confounders in the multivariable models. This could lead to the presence of residual (unmeasured) confounding in our multivariable models. To limit this, we used the Davies comorbidity score which represents multiple somatic comorbidities. Second, in this study withdrawal was defined as the elective cessation of renal replacement therapy without immediate medical indication to do so. This coding, however, does not allow for identifying the underlying

reasons for dialysis withdrawal. To be able to investigate the relationship of different factors on the risk of withdrawal from dialysis a clearer and exacter definition is needed to limit heterogeneous results from research. Furthermore, qualitative studies could aid in investigating the decision-making process from a patient and clinician perspective [6].

Future implications

This study indicates that presence of anxiety and depressive symptoms are not only associated with increased hospitalization rate and increased mortality, but also to dialysis withdrawal, independent of somatic comorbidity. Our findings suggest that screening for symptoms of anxiety and depression may be useful to increase awareness in patients and clinicians about these symptoms and their effect on decision making. We acknowledge that the ability to distinguish demoralization due to somatic burdens from anxiety and depressive disorders remains a challenge. Our study shows that the cut off of common screenings questionnaires may be helpful in understanding the possible risk of these symptoms in relation to dialysis withdrawal. Also, it can be useful to discuss possible treatment options and to make an informed decision on withdrawal. Future studies should further investigate the effect of mental health on end-of-life decisions in dialysis patients, and the role of other patient characteristics like ethnicity and religion, in large multi-ethnic samples. This will help to develop clinical guidelines to improve care for dialysis patients who consider dialysis withdrawal.

Conclusion

Withdrawal from dialysis therapy is associated with anxiety and depressive symptoms, independent of somatic comorbidities. Further (qualitative) studies are needed to investigate the decision making of patients and clinicians regarding dialysis withdrawal. Increase in knowledge of factors that influence the decisions of dialysis withdrawal could aid patients and clinicians in making an informed decision.

List of Abbreviations

BAI	Beck Anxiety Inventory
BDI-II	Beck's Depression Inventory, version 2
CCMO	Central Committee on Research Involving Human Subjects
CI	Confidence Interval
DIVERS	Depression-related factors and outcomes In dialysis patients with Various Ethnicities and Races Study
ERA-EDTA	European Renal Association-European Dialysis and Transplant Association
ESKD	End-Stage Kidney Disease
HR	Hazard Ratio
MCS	Mental Component Score
MEC-U	Medical Research Ethics Committees United
PCS	Physical Component Score
QoL	Quality of Life (QoL)
RET	2012 Guideline External Testing 2012
SF-12	12-Item Short Form Health Survey
SF-36	36-Item Short Form Health Survey

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12882-023-03267-2>.

Supplementary Material 1

Acknowledgements

We thank the nurses and participating dialysis centers of the DIVERS study for the collection and management of the data. We gratefully thank all the patients who participated in the DIVERS study.

Authors' contributions

ES, RS, EN, AH, CS and BB contributed to the conceptualization of the research question and hypotheses. Data was collected by ES and RS. Analysis was conducted by ES and RS. CS, BB and AH supervised the project. ES and RS wrote the manuscript in close cooperation with EN, CS, BB and AH. All authors contributed to, reviewed and approved the final version of the manuscript.

Funding

This project was supported by grants from the Dutch Renal Association (grant ID: SB 174) and the OLVG hospital in Amsterdam. The funders did not have any role in study design, writing the report, or the decision to submit the report for publication.

Data Availability

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

This study was approved by the medical ethics committee of the Medical Research Ethics Committees United (MEC-U) of which the initiating hospital the OLVG is associated with. All medical research bureaus of participating centers and their associated centers (Haga hospital, HMC Hospital and VU University Medical Centre) evaluated the approval and signed a research declaration in accordance with Dutch external testing guideline (RET 2012) of the Central Committee on Research Involving Human Subjects (CCMO). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all participants. Legal guardians signed informed consent for participants who were unable to sign the informed consent themselves, either due to cognitive disabilities or illiteracy.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Received: 27 October 2021 / Accepted: 10 July 2023

Published online: 24 July 2023

References

1. Khou V, De La Mata NL, Morton RL, Kelly PJ, Webster AC. Cause of death for people with end-stage kidney disease withdrawing from treatment in Australia and New Zealand. *Nephrol Dial Transplant*. 2021;36(8):1527–37.
2. Chan S, Marshall MR, Ellis RJ, Ranganathan D, Hawley CM, Johnson DW, et al. Haemodialysis withdrawal in Australia and New Zealand: a binational registry study. *Nephrol Dial Transplant*. 2020;35(4):669–76.
3. Fissell RB, Bragg-Gresham JL, Lopes AA, Cruz JM, Fukuhara S, Asano Y, et al. Factors associated with "do not resuscitate" orders and rates of withdrawal from hemodialysis in the international DOPPS. *Kidney Int*. 2005;68(3):1282–8.

4. van Biesen W, van de Lijstgaarden MW, Brown EA, Michel JP, van Munster BC, Jager KJ, et al. Nephrologists' perceptions regarding dialysis withdrawal and palliative care in Europe: lessons from a european renal best practice survey. *Nephrol Dial Transplant*. 2015;30(12):1951–8.
5. McDade-Montez EA, Christensen AJ, Cvengros JA, Lawton WJ. The role of depression symptoms in dialysis withdrawal. *Health psychology: official journal of the Division of Health Psychology American Psychological Association*. 2006;25(2):198–204.
6. Grubbs V, Tuot DS, Powe NR, O'Donoghue D, Chesla CA. System-Level Barriers and Facilitators for Foregoing or withdrawing Dialysis: a qualitative study of nephrologists in the United States and England. *Am J Kidney Dis*. 2017;70(5):602–10.
7. Murphy E, Germain MJ, Cairns H, Higginson IJ, Murtagh FE. International variation in classification of dialysis withdrawal: a systematic review. *Nephrol Dial Transplant*. 2014;29(3):625–35.
8. Qazi HA, Chen H, Zhu M. Factors influencing dialysis withdrawal: a scoping review. *BMC Nephrol*. 2018;19(1):96.
9. Palmer S, Vecchio M, Craig JC, Tonelli M, Johnson DW, Nicolucci A, et al. Prevalence of depression in chronic kidney disease: systematic review and meta-analysis of observational studies. *Kidney Int*. 2013;84(1):179–91.
10. Schouten RW, Haverkamp GL, Loosman WL, Chandie Shaw PK, van Ittersum FJ, Smets YFC et al. Anxiety symptoms, mortality, and hospitalization in patients receiving maintenance Dialysis: a Cohort Study. *Am J Kidney Dis*. 2019.
11. Lacson E Jr, Li NC, Guerra-Dean S, Lazarus M, Hakim R, Finkelstein FO. Depressive symptoms associate with high mortality risk and dialysis withdrawal in incident hemodialysis patients. *Nephrol Dial Transplant*. 2012;27(7):2921–8.
12. Van Biesen W, Lameire N, Veys N, Vanderhaeghe B. From curing to caring: one character change makes a world of difference. Issues related to withholding/withdrawing renal replacement therapy (RRT) from patients with important co-morbidities. *Nephrol Dial Transplant*. 2004;19(3):536–40.
13. Haverkamp GL, Loosman WL, Franssen CF, Kema IP, van Diepen M, Dekker FW, et al. The role of tryptophan degradation in the association between inflammatory markers and depressive symptoms in chronic dialysis patients. *Nephrol Dial Transplant*. 2017;32(6):1040–7.
14. Haverkamp GL, Loosman WL, Schouten RW, Franssen CF, Kema IP, van Diepen M, et al. Differences in the association of inflammation and tryptophan with depressive symptoms between white and non-white chronic dialysis patients. *Gen Hosp Psychiatry*. 2018;50:76–82.
15. Haverkamp GL, Loosman WL, van den Beukel TO, Hoekstra T, Dekker FW, Chandie Shaw PK, et al. The association of acculturation and depressive and anxiety symptoms in immigrant chronic dialysis patients. *Gen Hosp Psychiatry*. 2016;38:26–30.
16. Loosman WL, de Jong RW, Haverkamp GLG, van den Beukel TO, Dekker FW, Siebert CEH, et al. The Stability of type D personality in Dialysis Patients. *Int J Behav Med*. 2018;25(1):85–92.
17. Loosman WL, Haverkamp GLG, van den Beukel TO, Hoekstra T, Dekker FW, Chandie Shaw PK et al. Depressive and anxiety symptoms in dutch immigrant and native Dialysis patients. *J Immigr Minor Health*. 2018.
18. NZA. 'Scan' of the health insurance market 2016 [In Dutch: Marktscan Zorgverzekeringsmarkt 2016]: NZa; 2016 [updated 15th December 2017. Available from: https://puc.overheid.nl/doc/PUC_3484_22/1
19. van Dijk PC, Jager KJ, de Charro F, Collart F, Cornet R, Dekker FW, et al. Renal replacement therapy in Europe: the results of a collaborative effort by the ERA-EDTA registry and six national or regional registries. *Nephrol Dial Transplant*. 2001;16(6):1120–9.
20. Davies SJ, Phillips L, Naish PF, Russell GI. Quantifying comorbidity in peritoneal dialysis patients and its relationship to other predictors of survival. *Nephrol Dial Transplant*. 2002;17(6):1085–92.
21. StatLine [Internet] CBS. 2019 [cited 7 Jul 2019]. Available from: <https://open-data.cbs.nl/statline/#/CBS/nl/>
22. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. *J Consult Clin Psychol*. 1988;56(6):893–7.
23. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. *Arch Gen Psychiatry*. 1961;4(6):561–71.
24. Muntingh AD, van der Feltz-Cornelis CM, van Marwijk HW, Spinhoven P, Penninx BW, van Balkom AJ. Is the Beck anxiety inventory a good tool to assess the severity of anxiety? A primary care study in the Netherlands Study of Depression and anxiety (NESDA). *BMC Fam Pract*. 2011;12:66.
25. Osman A, Kopper BA, Barrios FX, Osman JR, Wade T. The Beck anxiety inventory: reexamination of factor structure and psychometric properties. *J Clin Psychol*. 1997;53(1):7–14.
26. Beck AT, Steer RA, Brown GK. BDI-II: Beck Depression Inventory Manual. 2nd ed. TX: Psychological Corporation; 1996.
27. Loosman WL, Siebert CE, Korzec A, Honig A. Validity of the hospital anxiety and Depression Scale and the Beck Depression Inventory for use in end-stage renal disease patients. *Br J Clin Psychol*. 2010;49(Pt 4):507–16.
28. Ware J, Snowww K, Ma K, Bg G. SF36 Health Survey: Manual and Interpretation Guide. Lincoln, RI: Quality Metric, Inc, 1993. 1993;30.
29. Lacson E, Xu J, Lin S-F, Dean SG, Lazarus JM, Hakim RM. A comparison of SF-36 and SF-12 Composite Scores and subsequent hospitalization and mortality risks in Long-Term Dialysis Patients. *Clin J Am Soc Nephrol*. 2010;5(2):252–60.
30. Schouten RW, Haverkamp GL, Loosman WL, Chandie Shaw PK, van Ittersum FJ, Smets YFC, et al. Anxiety symptoms, mortality, and hospitalization in patients receiving maintenance Dialysis: a Cohort Study. *Am J Kidney Dis*. 2019;74(2):158–66.
31. Lopes AA, Bragg J, Young E, Goodkin D, Mapes D, Combe C, et al. Depression as a predictor of mortality and hospitalization among hemodialysis patients in the United States and Europe. *Kidney Int*. 2002;62(1):199–207.
32. Farrokhi F, Abedi N, Beyene J, Kurdyak P, Jassal SV. Association between depression and mortality in patients receiving long-term dialysis: a systematic review and meta-analysis. *Am J Kidney Dis*. 2014;63(4):623–35.
33. Bulow HH, Sprung CL, Reinhart K, Prayag S, Du B, Armaganidis A, et al. The world's major religions' points of view on end-of-life decisions in the intensive care unit. *Intensive Care Med*. 2008;34(3):423–30.
34. Sprung CL, Maia P, Bulow HH, Ricou B, Armaganidis A, Baras M, et al. The importance of religious affiliation and culture on end-of-life decisions in european intensive care units. *Intensive Care Med*. 2007;33(10):1732–9.
35. Patel SS, Shah VS, Peterson RA, Kimmel PL. Psychosocial variables, quality of life, and religious beliefs in ESRD patients treated with hemodialysis. *Am J Kidney Dis*. 2002;40(5):1013–22.
36. Schouten RW, Haverkamp GL, Loosman WL, Chandie Shaw PK, van Ittersum FJ, Smets YFC, et al. Ethnic differences in the Association of depressive symptoms with clinical outcome in Dialysis Patients. *J Racial Ethn Health Disparities*. 2019;6(5):990–1000.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.